Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics (PRQR) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for severe genetic disorders. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and strategic partnerships related to its Axiomer RNA editing platform.
Access verified press releases and objective news coverage spanning key areas including clinical trial progress, research collaborations, and intellectual property advancements. Our curated collection ensures you stay informed about PRQR's work in addressing unmet medical needs through precise RNA modification technologies.
Discover updates on therapeutic programs targeting conditions like cystic fibrosis and Rett syndrome, financial disclosures, and partnership announcements with industry leaders. All content is sourced from official channels and reputable financial publications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PRQR's latest scientific advancements and corporate updates. Check regularly for new developments in RNA editing innovation and the company's progress toward delivering transformative genetic medicines.
ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the RNA Editing Summit from June 18-20, 2024, in Boston. Gerard Platenburg, Chief Scientific Officer and Co-Founder, will present on June 20 at 2:00pm ET. The presentation, titled “Developing Axiomer RNA Editing Technology Towards Clinical Development,” will focus on ProQR’s ADAR-mediated Axiomer RNA editing technology, optimization strategies, and the AX-0810 program targeting NTCP for cholestatic diseases. The presentation will also cover in vivo models of biomarkers for NTCP and will be accessible on ProQR’s website under Presentations & Publications.
ProQR Therapeutics NV. (Nasdaq: PRQR) reported Q1 2024 financial results, highlighting preclinical data for the AX-0810 program targeting NTCP for cholestatic diseases. The company presented successful defense of its IP estate and announced Martin Maier, PhD's nomination to the Board. ProQR emphasized its strong cash position of €102.7 million providing runway into mid-2026.
ProQR Therapeutics NV announced preclinical proof of concept data for its AX-0810 Axiomer™ RNA editing program targeting NTCP for cholestatic diseases. The data, presented at the ASGCT Annual Meeting, revealed significant progress in RNA editing technology. The AX-0810 program aims to reduce bile acid concentration in the liver by targeting NTCP, representing a promising approach for cholestatic disorders. The company plans to advance the program to the clinic in late 2024/early 2025, with additional milestones expected for the Axiomer pipeline.
FAQ
What is the current stock price of Proqr Therapeuti (PRQR)?
What is the market cap of Proqr Therapeuti (PRQR)?
